The Court of Appeals for the Federal Circuit rendered its decision in Vectura Limited v. GlaxoSmithKline LLC on November 19, 2020, affirming the District of Delaware’s prior finding that GlaxoSmithKline infringed the claims of Vectura’s U.S. Patent No. 8,303,991 directed to inhalers. See http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1054.OPINION.11-19-2020_1688174.pdf.